Carcinocythemia: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
[[File:Carcinocythemia_-_malignant_tumour_cells_in_peripheral_blood_(cropped_v1).png| | {{SI}} | ||
{{Infobox medical condition | |||
| name = Carcinocythemia | |||
| image = [[File:Carcinocythemia_-_malignant_tumour_cells_in_peripheral_blood_(cropped_v1).png|250px]] | |||
| caption = Malignant tumor cells in peripheral blood | |||
| field = [[Hematology]] | |||
| synonyms = Carcinoma cell leukemia | |||
| symptoms = [[Fatigue]], [[anemia]], [[thrombocytopenia]], [[leukocytosis]] | |||
| complications = [[Infection]], [[bleeding]], [[organ failure]] | |||
| onset = Variable, often in advanced stages of cancer | |||
| duration = Chronic | |||
| causes = [[Metastatic cancer]] | |||
| risks = Advanced [[cancer]], [[immunosuppression]] | |||
| diagnosis = [[Blood smear]], [[flow cytometry]], [[bone marrow biopsy]] | |||
| differential = [[Leukemia]], [[lymphoma]], [[myeloproliferative neoplasm]] | |||
| treatment = [[Chemotherapy]], [[radiation therapy]], [[supportive care]] | |||
| prognosis = Poor, often associated with advanced cancer | |||
| frequency = Rare | |||
}} | |||
'''Carcinocythemia''' is a rare and severe condition characterized by the presence of malignant [[carcinoma]] cells in the [[peripheral blood]]. This phenomenon is also known as carcinoma cell leukemia. It is a manifestation of advanced [[metastatic cancer]] and indicates a poor prognosis. | |||
==Pathophysiology== | ==Pathophysiology== | ||
Carcinocythemia occurs when carcinoma cells from a primary tumor enter the bloodstream and circulate as free cells. These cells can originate from various types of carcinomas, including [[breast cancer]], [[lung cancer]], [[prostate cancer]], and [[gastrointestinal cancer]]. The presence of these cells in the blood is indicative of widespread [[metastasis]] and significant tumor burden. | Carcinocythemia occurs when carcinoma cells from a primary tumor enter the bloodstream and circulate as free cells. These cells can originate from various types of carcinomas, including [[breast cancer]], [[lung cancer]], [[prostate cancer]], and [[gastrointestinal cancer]]. The presence of these cells in the blood is indicative of widespread [[metastasis]] and significant tumor burden. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
Patients with carcinocythemia often present with symptoms related to their primary malignancy. Common symptoms include [[fatigue]], [[weight loss]], and [[anemia]]. Due to the high tumor burden, patients may also experience complications such as [[thrombocytopenia]], [[leukopenia]], and [[disseminated intravascular coagulation]] (DIC). | Patients with carcinocythemia often present with symptoms related to their primary malignancy. Common symptoms include [[fatigue]], [[weight loss]], and [[anemia]]. Due to the high tumor burden, patients may also experience complications such as [[thrombocytopenia]], [[leukopenia]], and [[disseminated intravascular coagulation]] (DIC). | ||
==Diagnosis== | ==Diagnosis== | ||
The diagnosis of carcinocythemia is made through the identification of malignant cells in a peripheral blood smear. These cells are typically identified by their large size, irregular shape, and high nuclear-to-cytoplasmic ratio. Additional diagnostic tools may include [[flow cytometry]], [[immunohistochemistry]], and [[molecular diagnostics]] to confirm the origin and type of carcinoma cells. | The diagnosis of carcinocythemia is made through the identification of malignant cells in a peripheral blood smear. These cells are typically identified by their large size, irregular shape, and high nuclear-to-cytoplasmic ratio. Additional diagnostic tools may include [[flow cytometry]], [[immunohistochemistry]], and [[molecular diagnostics]] to confirm the origin and type of carcinoma cells. | ||
==Treatment== | ==Treatment== | ||
The treatment of carcinocythemia is challenging and primarily focuses on managing the underlying malignancy. Therapeutic options may include [[chemotherapy]], [[targeted therapy]], and [[immunotherapy]]. Supportive care measures are also essential to manage symptoms and complications such as anemia and DIC. | The treatment of carcinocythemia is challenging and primarily focuses on managing the underlying malignancy. Therapeutic options may include [[chemotherapy]], [[targeted therapy]], and [[immunotherapy]]. Supportive care measures are also essential to manage symptoms and complications such as anemia and DIC. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for patients with carcinocythemia is generally poor due to the advanced stage of the disease and the extensive spread of cancer cells. The presence of carcinoma cells in the blood is associated with a high risk of mortality. | The prognosis for patients with carcinocythemia is generally poor due to the advanced stage of the disease and the extensive spread of cancer cells. The presence of carcinoma cells in the blood is associated with a high risk of mortality. | ||
==See Also== | ==See Also== | ||
* [[Leukemia]] | * [[Leukemia]] | ||
| Line 23: | Line 36: | ||
* [[Chemotherapy]] | * [[Chemotherapy]] | ||
* [[Immunotherapy]] | * [[Immunotherapy]] | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
==External Links== | ==External Links== | ||
{{WikiDoc}} | {{WikiDoc}} | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
[[Category:Blood disorders]] | [[Category:Blood disorders]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
Latest revision as of 01:03, 6 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Carcinocythemia | |
|---|---|
| File:Carcinocythemia - malignant tumour cells in peripheral blood (cropped v1).png | |
| Synonyms | Carcinoma cell leukemia |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fatigue, anemia, thrombocytopenia, leukocytosis |
| Complications | Infection, bleeding, organ failure |
| Onset | Variable, often in advanced stages of cancer |
| Duration | Chronic |
| Types | N/A |
| Causes | Metastatic cancer |
| Risks | Advanced cancer, immunosuppression |
| Diagnosis | Blood smear, flow cytometry, bone marrow biopsy |
| Differential diagnosis | Leukemia, lymphoma, myeloproliferative neoplasm |
| Prevention | N/A |
| Treatment | Chemotherapy, radiation therapy, supportive care |
| Medication | N/A |
| Prognosis | Poor, often associated with advanced cancer |
| Frequency | Rare |
| Deaths | N/A |
Carcinocythemia is a rare and severe condition characterized by the presence of malignant carcinoma cells in the peripheral blood. This phenomenon is also known as carcinoma cell leukemia. It is a manifestation of advanced metastatic cancer and indicates a poor prognosis.
Pathophysiology[edit]
Carcinocythemia occurs when carcinoma cells from a primary tumor enter the bloodstream and circulate as free cells. These cells can originate from various types of carcinomas, including breast cancer, lung cancer, prostate cancer, and gastrointestinal cancer. The presence of these cells in the blood is indicative of widespread metastasis and significant tumor burden.
Clinical Presentation[edit]
Patients with carcinocythemia often present with symptoms related to their primary malignancy. Common symptoms include fatigue, weight loss, and anemia. Due to the high tumor burden, patients may also experience complications such as thrombocytopenia, leukopenia, and disseminated intravascular coagulation (DIC).
Diagnosis[edit]
The diagnosis of carcinocythemia is made through the identification of malignant cells in a peripheral blood smear. These cells are typically identified by their large size, irregular shape, and high nuclear-to-cytoplasmic ratio. Additional diagnostic tools may include flow cytometry, immunohistochemistry, and molecular diagnostics to confirm the origin and type of carcinoma cells.
Treatment[edit]
The treatment of carcinocythemia is challenging and primarily focuses on managing the underlying malignancy. Therapeutic options may include chemotherapy, targeted therapy, and immunotherapy. Supportive care measures are also essential to manage symptoms and complications such as anemia and DIC.
Prognosis[edit]
The prognosis for patients with carcinocythemia is generally poor due to the advanced stage of the disease and the extensive spread of cancer cells. The presence of carcinoma cells in the blood is associated with a high risk of mortality.
See Also[edit]
References[edit]
<references group="" responsive="1"></references>
External Links[edit]
.png){kind=link}